Select Page

Blog

Large Pharma’s Embrace of Artificial Intelligence

Large Pharma’s Embrace of Artificial Intelligence

I was recently watching BioIDEA’s Biotech vs COVID-19 event. During the event our CEO, Andrew Satz, was asked about the viability of fully computational drug discovery and development. His answer surprised me. He discussed a number of legitimate hurdles that need to...

read more
The Depth, Vision and Progress of EVQLV

The Depth, Vision and Progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies' "Alumni in Conversation." The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the...

read more
EVQLV’s Evolutionary Algorithm Explained

EVQLV’s Evolutionary Algorithm Explained

https://youtu.be/qIW1o8jgRsk Our technology works by taking an antibody sequence of interest and performing evolutionary modeled mutagenesis, mimicking the natural selection inherent to antibody VDJ recombination and affinity maturation. Using large amounts of public...

read more
Andrew Satz on the Talent Finders Podcast

Andrew Satz on the Talent Finders Podcast

EVQLV's CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more. Give it a listen below. https://youtu.be/A2QoFVnD1Wc Timestamps: Andrew's...

read more